TRANSTHYRETIN AMYLOIDOSIS
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot every 3 months shows promise for rare nerve disease
Disease control CompletedThis study tested a new medicine called vutrisiran in 164 adults with a rare, inherited nerve disease (hATTR amyloidosis). Participants received either vutrisiran as a shot every 3 months or another drug every 3 weeks. The goal was to see if vutrisiran could slow nerve damage and…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Can MRI and electrical tests catch nerve disease before symptoms start?
Knowledge-focused CompletedThis study looked at 60 people with a genetic risk for familial amyloid neuropathy, a severe nerve disease. Researchers tested whether MRI scans and a special electrical test called MUNIX could detect early nerve changes before symptoms appear. The goal was to find better ways to…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: NA • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated May 17, 2026 01:49 UTC
-
Protein clues may predict onset of rare genetic disease
Knowledge-focused CompletedThis study followed 37 people who carry a genetic mutation for hereditary ATTR amyloidosis but do not yet have symptoms. Over five years, researchers measured a specific misfolded protein in the blood to see if it changes when the disease starts or when treatment is needed. The g…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC